GlaxoSmithKline's (GSK) VC fund, SR One, is looking to invest in a company that is developing...


GlaxoSmithKline's (GSK) VC fund, SR One, is looking to invest in a company that is developing drugs for the early detection of Alzheimer’s disease and a treatment for it. Separately, GSK is applying Shinya Yamanaka’s Nobel Prize-winning discovery in stem cells to help find out if experimental drugs have heart risks. Around half of drugs that fail due to safety do so because of the effects on the heart.

From other sites
Comments (2)
  • Ross Breckenridge
    , contributor
    Comments (6) | Send Message
     
    The problem is that this makes the supposition that the "amyloid hypothesis" of AD pathogenesis is correct. It's putting yet more monetary eggs in the same basket.
    23 Oct 2012, 09:26 AM Reply Like
  • prvakil
    , contributor
    Comments (2) | Send Message
     
    I think Prana biotech.(PRAN) will be the place to invest for Alzimer treatment.
    24 Oct 2012, 03:28 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs